申请人:Rhone-Poulenc Industries
公开号:US04034090A1
公开(公告)日:1977-07-05
New cephalosporin derivatives of the formula: ##STR1## in which either (a) R.sub.1 is hydrogen, acetoxy, azido or heterocyclylthio or heterocyclylcarbonylthio which is (1,3,4-thiadiazol-2-yl)-thio which is unsubstituted or substituted by straight or branched chain C.sub.1-4 alkyl or alkoxy, straight or branched chain C.sub.1-4 alkylthio, straight or branched chain C.sub.1-4 alkylsulphonyl, amino or acetylamino; (1,2,3,4-tetrazol-5-yl)-thio which is unsubstituted or substituted in the 1-position by straight or branched chain C.sub.1-4 alkyl, hydroxy straight or branched chain C.sub.1-4 alkyl, phenyl or hydroxyphenyl, or in the 2-position by straight or branched chain C.sub.1-4 alkyl or hydroxy straight or branched chain C.sub.1-4 alkyl; (1,2,4-triazol-3-yl)-thio, (4-methyl-1,3-thiazol-2-yl)-thio, (3-methyl-1,2,4-thiadiazol-5-yl)-thio or (1,2,3-thiadiazol-4-yl)-carbonylthio, and R.sub.2 is carboxy or a radical of the formula: ##STR2## in which the radical: ##STR3## is a radical which can be easily removed enzymatically, and in which R.sub.3 is hydrogen or straight or branched chain C.sub.1-4 alkyl and R.sub.4 is straight or branched chain C.sub.1-4 alkyl or cyclohexyl; or (b) R.sub.1 is a pyridinio ion and R.sub.2 is a carboxylato ion, and pharmaceutically acceptable non-toxic metal salts thereof and addition salts thereof with nitrogen containing bases possess valuable anti-bacterial properties, showing activity against both Gram-positive and Gram-negative bacteria.
新型头孢菌素衍生物的通式为:##STR1## 其中,(a) R1为氢、乙酸氧、叠氮或杂环硫或杂环羰基硫,具体为未取代或被直链或支链C1-4烷基或烷氧基、直链或支链C1-4烷基硫、直链或支链C1-4烷基磺酰基、氨基或乙酰氨基取代的(1,3,4-噻二唑-2-基)硫;未取代或1位被直链或支链C1-4烷基、羟基直链或支链C1-4烷基、苯基或羟基苯基取代,或2位被直链或支链C1-4烷基或羟基直链或支链C1-4烷基取代的(1,2,3,4-四唑-5-基)硫;(1,2,4-三唑-3-基)硫、(4-甲基-1,3-噻唑-2-基)硫、(3-甲基-1,2,4-噻二唑-5-基)硫或(1,2,3-噻二唑-4-基)羰基硫,R2为羧基或以下通式所示的基团:##STR2## 其中,##STR3## 是一个可被酶轻易移除的基团,R3为氢或直链或支链C1-4烷基,R4为直链或支链C1-4烷基或环己基;或(b) R1为吡啶鎓离子,R2为羧基离子,以及其药用可接受的非毒性金属盐和与含氮碱形成的加成盐,具有宝贵的抗菌特性,对革兰氏阳性和革兰氏阴性细菌均显示出活性。